Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

Leonie RatzChiara BrambillascaLeandra BartkeMaxim A HuetzenJonas GoergensOrsolya LeideckerRon D JachimowiczMarieke van de VenNatalie ProostBjørn SiteurRenske de Korte-GrimmerinkPeter BouwmanEmilia M PulverRoebi de BruijnJörg IsenseeTim HuchoGaurav PandeyMaarten van LohuizenPeter MallmannHans Christian ReinhardtJos JonkersJulian Puppe

Published in: Breast cancer research : BCR (2022)

Taken together, we identified a synthetic lethal interaction between EZH2 and ATM and propose this synergistic interaction as a novel molecular combination for the treatment of BRCA1-mutant breast cancer.

Keyphrases

breast cancer risk
dna damage
dna repair
dna damage response
long non coding rna
long noncoding rna
wild type
oxidative stress
combination therapy